LFG
ABUS icon

Larson Financial Group’s Arbutus Biopharma ABUS Stock Holding History

Larson Financial Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.22K Sell
716
-45
-6% -$197 ﹤0.01% 2794
2025
Q4 		$3.66K Buy
761
+22
+3% +$99 ﹤0.01% 2580
2025
Q3 		$3.35K Buy
+739
New +$2.71K ﹤0.01% 2506
2021
Q1 		– Sell
-901
Closed -$3K – 820
2020
Q4 		$3K Buy
+901
New +$3.15K ﹤0.01% 591

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Larson Financial Group's ABUS Position: Q1 2026 in Review

Larson Financial Group reduced its Arbutus Biopharma (ABUS) stake by 5.9% in Q1 2026, selling an estimated $197 and leaving 716 shares worth $3.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2794.

Larson Financial Group first reported a position in ABUS in Q4 2020 and has held it in 4 quarters since. The position peaked at $3.66K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Larson Financial Group held 716 shares of Arbutus Biopharma worth $3.22K as of Q1 2026.
  • Larson Financial Group sold 45 Arbutus Biopharma shares in Q1 2026, an estimated $197.
  • Arbutus Biopharma made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2794 holding.
  • Larson Financial Group first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 4 quarters since.
  • Larson Financial Group's Arbutus Biopharma position peaked at $3.66K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.